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Key points
 Adiponectin is an adipokine with anti-inflammatory and anti-diabetic properties. Hypo-
adiponectinaemia is closely associated with endothelial dysfunction and insulin resistance
in obesity and diabetes.
 Insulin resistance is present in muscle microvasculature and this may contribute to decreased
insulin delivery to, and action in, muscle.
 In this study we examined whether adiponectin ameliorates metabolic insulin resistance by
affecting muscle microvascular recruitment.
 We demonstrated that a high-fat diet induces vascular adiponectin and insulin resistance
but globular adiponectin administration can restore vascular insulin responses and improve
insulin’s metabolic action via an AMPK- and nitric oxide-dependent mechanism.
 This suggests that globular adiponectin might have a therapeutic potential for improving
insulin resistance and preventing cardiovascular complications in patients with diabetes via
modulation of microvascular insulin responses.
Abstract Hypoadiponectinaemia is closely associated with endothelial dysfunction and insulin
resistance, and microvasculature plays a critical role in the regulation of insulin action in muscle.
Here we tested whether adiponectin replenishment could improve metabolic insulin sensitivity
in male rats fed a high-fat diet (HFD) via the modulation of microvascular insulin responses.
Male Sprague–Dawley rats were fed either a HFD or low-fat diet (LFD) for 4 weeks. Small
resistance artery myograph changes in tension, muscle microvascular recruitment and metabolic
response to insulin were determined. Compared with rats fed a LFD, HFD feeding abolished
the vasodilatory actions of globular adiponectin (gAd) and insulin on pre-constricted distal
saphenous arteries. Pretreatment with gAd improved insulin responses in arterioles isolated from
HFD rats, which was blocked by AMP-activated protein kinase (AMPK) inhibition. Similarly,
HFD abolished microvascular responses to either gAd or insulin and decreased insulin-stimulated
glucose disposal by 60%. However, supplementing gAd fully rescued insulin’s microvascular
action and significantly improved the metabolic responses to insulin in HFD male rats and these
actions were abolished by inhibition of either AMPK or nitric oxide production. We conclude
that HFD induces vascular adiponectin and insulin resistance but gAd administration can restore
vascular insulin responses and improve insulin’s metabolic action via an AMPK- and nitric
oxide-dependent mechanism in male rats.
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Introduction
Adiponectin is a well-known insulin sensitizer and patients
with obesity and diabetes exhibit hypoadiponectinaemia
(Arita et al. 1999; Hotta et al. 2000; Weyer et al. 2001).
Similarly, obese and diabetic animals have low plasma
adiponectin levels and replenishment of adiponectin
ameliorates insulin resistance in liver, adipose tissue and
skeletal muscle (Berg et al. 2001; Combs et al. 2001; Fruebis
et al. 2001; Yamauchi et al. 2001). In normotensive young
spontaneously hypertensive rats hypoadiponectinaemia
plays a causal role in the development of vascular
insulin resistance (Xing et al. 2013). Adenovirus-mediated
adiponectin overexpression improves muscle insulin
sensitivity in Wistar rats (Satoh et al. 2005). Hypo-
adiponectinaemia is also associated with endothelial
dysfunction in obese KKAy (Ohashi et al. 2006) and
diabetic (db/db) mice (Lee et al. 2012) while adiponectin
repletion significantly improves endothelial function.
Adiponectin binds to adiponectin receptors 1 and
2 (AdipoR1 and AdipoR2) to exert its biological
effects, including vasodilatation and insulin sensitization
(Kadowaki & Yamauchi, 2005). Multiple mechanisms may
contribute to the insulin-sensitizing action of adiponectin,
including the activation of AMP-activated protein kinase
(AMPK) and peroxisome proliferator-activated receptor
α, and stimulation of fatty acid oxidation (Nedvı́dková
et al. 2005). We have recently demonstrated that globular
adiponectin (gAd) can enhance muscle insulin action by
recruiting capillaries to increase microvascular perfusion
and muscle insulin delivery and action in healthy, insulin
sensitive rats, which links the adiponectin’s vascular effects
to its metabolic effects and provides a new mechanistic
insight into the insulin-sensitizing effect of adiponectin in
vivo (Zhao et al. 2013).
Muscle microvasculature provides an endothelial
surface area for substrate exchange between plasma and
muscle interstitium and plays a pivotal role in the
regulation of insulin delivery to, and action in, muscle
(Clerk et al. 2004; Barrett et al. 2009). We and others
have shown that factors that increase muscle micro-
vascular perfusion, such as exercise, insulin, glucagon-like
peptide1, ranolazine and angiotensin II type 1 receptor
blockade are all capable of increasing muscle insulin
delivery and action (Vincent et al. 2004; Inyard et al.
2007; Chai et al. 2011, 2012; Fu et al. 2013). For
insulin, blocking nitric oxide (NO) synthase inhibits
its action to recruit microvasculature and this reduces
insulin-stimulated glucose disposal by up to 40% (Vincent
et al. 2003). Insulin’s microvascular effect is blunted or
abolished in the insulin-resistant states in both animal
models and humans (de Jongh et al. 2004; Clerk et al. 2006;
Liu et al. 2009). Mounting evidence from both clinical and
animal studies suggests that microvascular dysfunction
is present in obesity which may play a pathogenesis
role in the development of metabolic insulin resistance
in obesity and type 2 diabetes (Wallis et al. 2002; de
Jongh et al. 2004; Clerk et al. 2006; Jonk et al. 2007).
We considered that enhancing microvascular perfusion in
insulin-resistant states could improve insulin’s metabolic
actions by augmenting insulin delivery to muscle. Indeed,
we have recently reported that systemic administration of
losartan was able to recruit muscle microvasculature and
restore fully muscle insulin sensitivity in rats receiving
systemic lipid infusion (Wang et al. 2013).
In the present study we examined the acute micro-
vascular and metabolic insulin responses in the presence
or absence of gAd administration in a rodent model of
chronic insulin resistance induced by 4 weeks of high-fat
diet (HFD). Isolated distal saphenous arteries were used
to assess the vasoactive actions of gAd and insulin ex
vivo and contrast-enhanced ultrasound (CEU) technology
was used to assess microvascular perfusion in vivo. Our
results suggest that HFD rats exhibit both gAd and
insulin resistance in small resistance arteries and micro-
circulation, and treatment with gAd restores vascular
insulin responses and improves the metabolic action of
insulin in muscle of HFD rats.
Methods
Ethical approval
The study conforms to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (publication No. 85-23, revised 1996). The study
protocols were approved by the Animal Care and Use
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Committee of the University of Virginia, which conforms
to the principles of UK regulations, as described in
Drummond (2009).
Animal preparations and experimental protocols
Adult male Sprague–Dawley rats (200–250 g, Charles River
Laboratories, Wilmington, MA, USA) were placed on
either a high-fat diet (HFD, 60% calories from saturated
fat) or a low-fat diet (LFD, 10% calories from saturated
fat; Research Diets, New Brunswick, NJ, USA) for 4 weeks.
Rats were housed at 22±2°C on a 12 h light–dark cycle and
given water ad libitum. Rats were then fasted overnight and
anaesthetized with pentobarbital sodium (50 mg kg−1 I.P.,
Abbott Laboratories, North Chicago, IL, USA). They were
placed in a supine position on a heating pad to ensure
euthermia and intubated to maintain a patent airway.
The carotid artery and the jugular vein were cannulated
with PE50 polyethylene tubing (Fisher Scientific, Newark,
DE, USA) for blood pressure monitoring, arterial blood
sampling and various infusions. After a 30–45 min base-
line period to ensure haemodynamic stability and stable
anaesthesia, rats were studied under the following two
protocols. At the end of each study, rats were killed via a
pentobarbital sodium overdose.
In protocol 1, HFD rats (5 rats in this group) received
an I.P. injection of rat gAd (0.4 μg (g body wt)−1; Biovision
Inc., Mountain View, CA, USA). Hindlimb muscle micro-
vascular blood volume (MBV) and microvascular blood
flow velocity (MFV) were measured using CEU before,
and 30, 60 and 120 min after, gAd injection as previously
described (Vincent et al. 2004). Microvascular blood flow
(MBF) was calculated as the product of MBV and MFV.
In protocol 2 seven groups of rats were studied (5–6
rats in each group). Rats received a 2 h euglycaemic
hyperinsulinaemic clamp (3 mU kg−1 min−1) after an
I.P. injection of either rat gAd (0.4 μg (g body wt)−1)
or saline in the presence or absence of an I.P. injection of
Compound C (10 μg (g body wt)−1; Calbiochem, Billerica,
MA, USA) (McCullough et al. 2005) or L-NG-nitroarginine
methyl ester (L-NAME) co-infusion which started 30 min
prior to the initiation of insulin clamp. Arterial blood
glucose was determined every 10 min using an Accu-Chek
Advantage glucometer (Roche Diagnostics, Indianapolis,
IN, USA) and 30% dextrose was infused at a variable
rate to maintain blood glucose within 10% of basal.
Steady-state whole body glucose infusion rates were
measured. Hindlimb muscle MBV, MFV and MBF were
determined at time 0, 30, 60 and 120 min. Rats were then
killed and gastrocnemius muscle and aorta removed and
freeze-clamped for later measurement of adiponectin and
insulin signalling molecules using Western blot analysis as
described below.
Throughout the study, mean arterial blood pressure
(MAP) was monitored via a sensor connected to the
carotid arterial catheter (Harvard Apparatus, Holliston,
MA, USA and ADInstruments, Inc., Colorado Springs,
CO, USA). Pentobarbital sodium was infused throughout
the study at a variable rate to maintain steady levels of
anaesthesia and blood pressure. gAd was given as a single
intraperitoneal dose due to its long plasma half-life of
3–6 h (Pajvani et al. 2003; Hoffstedt et al. 2004).
Measurement of plasma adiponectin, insulin levels
and NO concentration
Plasma adiponectin was measured using an Adiponectin
Rat ELISA kit (Abcam, San Francisco, CA, USA), which
recognizes both full-length and globular adiponectin.
Plasma insulin concentrations were determined using a
Rat Insulin ELISA kit (Mercodia AB, Uppsala, Sweden).
Plasma NO levels were measured using a 280i Nitric
Oxide Analyser (GE Analytical Instruments, Boulder, CO,
USA), according to the manufacturer’s instructions. In
brief, ice-cold ethanol was mixed with plasma samples at
a ratio of 2:1, kept at 0°C for 30 min, and then centrifuged
at 18,000 g for 5 min. The supernatant was then used
for NO analysis based on a gas-phase chemiluminescent
reaction between NO and ozone.
Myograph studies
The distal saphenous arteries were dissected from
additional HFD and LFD rats (4–6 rats in each group)
immediately after the rats were anaesthetized. After
removing the adhering connective tissue, each artery was
cut into segments of 2 mm in length and vessel functions
were measured as previously described (Dong et al. 2013).
Briefly, each segment was mounted in a Multi Myograph
System (Danish Myo Technology, Aarhus, Denmark). The
organ chamber was filled with 6 ml of physiological salt
solution buffer (130 mM NaCl, 4.7 mM KCl, 1.6 mM
CaCl2, 1.17 mM MgSO4, 1.18 mM KH2PO4, 14.9 mM
NaHCO3, 0.026 mM EDTA and 5.5 mM glucose, pH 7.4),
which was constantly bubbled with 95% O2–5% CO2 and
maintained at 37°C. Each ring was stretched initially to an
optimal tension (5 mN) and then allowed to stabilize at
baseline tone. After pre-constriction with phenylephrine,
arterial responses to rat gAd and/or insulin were recorded.
Additional experiments were done in the presence of
Compound C (an AMPK inhibitor, 5 μM) (Meijer et al.
2013) or L-NAME (10 μM) pretreatment for 30 min.
Determination of protein expression
and phosphorylation in muscle and aorta
Protein expression of AdipoR1, AdipoR2, adaptor protein,
phosphotyrosine interaction, PH domain and leucine
zipper containing 1 (APPL1), total AMPK, endothelial
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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nitric oxide synthase (eNOS), protein kinase B (Akt)
and extracellular signal-regulated protein kinases 1 and
2 (ERK1/2), and the phosphorylation of AMPK, eNOS,
Akt and ERK1/2 in muscle or aorta were determined by
Western blot analysis, as previously described (Vincent
et al. 2004; Chai et al. 2008). Primary antibodies against
AdipoR1 (cat. no. ab70362) and AdipoR2 (ab77613) were
obtained from Abcam (Cambridge, MA, USA) and those
against APPL1 (no. 3276), phospho-AMPKα (Thr172)
(no. 2531), total AMPK (no. 5831), phospho-eNOS
(Ser1177) (no. 9571), total eNOS (no. 9572), phospho-Akt
(Ser473) (no. 9271), total Akt (no. 9272), phospho-ERK
(Thr202/Tyr204) (no. 4370) and total ERK1/2 (no. 4695)
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Molecular markers were used to verify the
molecular weights of the respective proteins. All blots
were developed using enhanced chemiluminescence (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). The
images were captured by the UVP imaging system (UVP
LLC, Upland, CA, USA) and quantified using ImageJ
software (National Institutes of Health, Besthesda, MD,
USA). For protein phosphorylation analyses, both the total
and phospho-specific densities were quantified and the
ratios of phospho-specific to total density calculated.
Statistical analysis
All data are presented as means ± SEM. Statistical analyses
were performed with SigmaStat 11.0 software (Systat
Software, Inc., San Jose, CA, USA), using either Student’s
t test or ANOVA with post hoc analysis as appropriate. A
P value < 0.05 was considered statistically significant.
Results
gAd restores endothelial function despite its blunted
vasodilatory action in small resistance arteries
from HFD fed rats
We first examined ex vivo the direct effects of gAd on
the isolated distal saphenous artery (<250 μm) as it
descends on the medial surface of the leg and at the
distal part of the medial thigh muscles, where muscle
gAd (µg/ml)









































































































































Figure 1. gAd improves vascular response to insulin in HFD rats via AMPK-mediated pathway
Each rat was fed with either a HFD or LFD for 4 weeks. The distal saphenous artery was isolated, pre-constricted
with phenylephrine (PE) and the vasodilatory responses to gAd (A and B) or insulin (C and D) with or without the
pretreatment with gAd (1 µg ml−1) and/or Compound C (5 µM) were determined. ∗P < 0.05 compared with HFD
control (ANOVA). #P < 0.05 compared with gAd + HFD. n = 6 each.
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microvascular perfusion was determined using CEU, a
significant distribution of small vessels arises from the
saphenous artery (Kochi et al. 2013). As shown in Fig. 1,
gAd dose-dependently relaxed the arterial ring isolated
from LFD rats but this effect was significantly blunted (by
50%, P < 0.05) in arteries from HFD rats, confirming
that HFD indeed induces resistance to gAd’s direct vaso-
dilatory action. Pretreatment of the arterial rings with
L-NAME abolished gAd’s vasodilatory action in both LFD
and HFD animals. Insulin induced a dose-dependent
vasodilatation in LFD rat arterial rings but similarly this
effect was impaired by HFD (50% less, P < 0.05). Pre-
treatment of the HFD rat arterial rings with gAd fully
restored the vascular response to insulin and this action
was totally blocked by AMPK inhibition with Compound
C. Similarly gAd pretreatment improved the arterial vaso-
dilatory response to ACh but not in the presence of
Compound C (Fig. 2A). Endothelium independent vaso-
dilatation was not affected by HFD feeding (Fig. 2B).
Neither L-NAME nor Compound C altered arterial resting
tension (Fig. 1).
HFD feeding abolishes gAd-induced microvascular
recruitment
We have recently reported that gAd potently recruits
muscle microvasculature in healthy insulin sensitive rats,
which leads to increased insulin delivery to, and action
in, muscle (Zhao et al. 2013). The above ex vivo findings
led us to examine whether gAd’s microvascular actions
were also blunted by HFD feeding. After 4 weeks of
HFD feeding, rats received gAd intraperitoneally at a
dose that potently recruits muscle microvasculature in
chow-fed rats (Zhao et al. 2013). HFD feeding completely
abolished gAd’s microvascular actions as evidenced by a
lack of changes in muscle MBV (0.91 ± 0.15, 0.98 ± 0.07
and 0.98 ± 0.15 times baseline at 30, 60 and 120 min,
respectively, P = 0.944), MFV (0.33 ± 0.03, 0.33 ± 0.02,
0.35 ± 0.03 and 0.31 ± 0.02 S−1 for 0, 30, 60 and
120 min, respectively, P = 0.764) and MBF (0.97 ± 0.23,
1.06 ± 0.16 and 0.97 ± 0.13 times baseline at 30, 60 and
120 min, respectively, P=0.704), indicating microvascular
resistance to gAd in these animals.
Adiponectin restores microvascular and improves
metabolic responses of insulin in HFD fed rats via
an AMPK-dependent pathway
As our ex vivo myograph study showed that the vaso-
dilatory action of gAd was reduced but gAd remained
effective in improving the vasodilatory effect of insulin in
small resistance arteries isolated from rats fed a HFD, we
next examined whether administration of gAd to HFD
fed rats could restore microvascular insulin responses.
Compared to LFD, 4 weeks of HFD feeding did not
alter body weight, blood pressure, plasma cholesterol,
triglycerides or glucose levels, but did significantly
increase plasma insulin concentrations and decrease
plasma adiponectin concentrations (Table 1). Injection
of gAd raised plasma adiponectin concentrations from
4.0 ± 0.3 μg ml−1 (0 min) to 6.7 ± 0.4 μg ml−1
(120 min) in HFD rats. Insulin infusion raised plasma
insulin concentrations to 670.1 ± 26.8, 718.6 ± 27.4
and 692.9 ± 25.1 pM, respectively, in LFD, HFD and
gAd + HFD groups (n = 5 each, P = 0.455).
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Figure 2. gAd restores endothelial responses to ACh in HFD rats
Each rat was fed either a HFD or LFD for 4 weeks. The distal saphenous artery was isolated, pre-constricted with
phenylephrine, and the vasodilatory responses to ACh (A) in the presence or absence of gAd and/or Compound
C, or sodium nitroprusside (SNP) (B) were determined. ∗P < 0.05 compared with LFD control (ANOVA). #P < 0.05
compared with HFD + gAd. n = 4–6 each.
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Table 1. Animal characteristics
Body weight (g) MAP (mmHg) Glucose (mM) Cholesterol (mM) Triglyceride (mM) Insulin (pM) Adiponectin (μg ml−1)
LFD 434.33 ± 10.53 111.86 ± 1.99 4.92 ± 0.10 1.38 ± 0.11 0.46 ± 0.09 102.0 ± 10.92 5.74 ± 0.52
HFD 459.50 ± 15.39 112.43 ± 1.78 4.91 ± 0.10 1.59 ± 0.11 0.55 ± 0.08 139.8 ± 7.52∗ 4.00 ± 0.31∗
Values are means ± SEM. LFD: low-fat diet; HFD: high-fat diet; MAP: mean arterial blood pressure. n = 5–6. ∗P < 0.05 compared with
LFD group.
Similar to previous reports (Vincent et al. 2004;
Zhao et al. 2013), insulin increased muscle MBV by
60% without altering MFV in LFD rats, which led to
a marked increase in muscle MBF (P < 0.05). However,
this insulin-mediated microvascular recruitment was
totally abolished by HFD feeding (Fig. 3), confirming
microvascular insulin resistance in these animals.
Administration of a single dose of gAd intraper-
itoneally before the insulin clamp completely restored
insulin-mediated microvascular recruitment in HFD rats.
Pretreatment with Compound C or L-NAME did not
alter the microvascular responses to insulin, but totally
abolished gAd-induced restoration of insulin responses
in muscle microvasculature in HFD rats (Fig. 3).
As shown in Fig. 4, HFD feeding for 4 weeks decreased
insulin-mediated whole body glucose disposal by 60%
(P < 0.001). Giving gAd before the insulin infusion
increased insulin-mediated whole-body glucose disposal
by 30% over the entire clamp period (P < 0.001,
ANOVA) and at the steady state (90–120 min; P < 0.05).
This effect was again inhibited by Compound C pre-
treatment or simultaneous infusion of L-NAME.
Adiponectin restores insulin-stimulated Akt and
eNOS phosphorylation in aorta but not in muscle
in HFD fed rats
The above results confirm the involvement of AMPK
and NO in adiponectin restoration of insulin’s vascular
responses in both the ex vivo small resistance artery and
the in vivo microvascular studies. To further examine
the underlying molecular mechanism, we compared the
adiponectin and insulin signalling pathways in both
metabolic tissue (muscle) and vasculature (aorta) between
animals fed either a HFD or LFD. The protein expressions
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Figure 3. gAd restores microvascular response to insulin in HFD rats via AMPK-mediated pathway
Each rat was fed a HFD for 4 weeks and then received an I.P. injection of either gAd (0.4 µg (g body wt)−1) or
saline followed by a 2 h euglycaemic hyperinsulinaemic clamp (3 mU kg−1 min−1) in the absence or presence of
Compound C pretreatment (I.P. 10 µg (g body wt)−1) or L-NAME infusion. A, Study protocol. B, MBV. C, MFV. D,
MBF. ∗P < 0.05 compared with LFD baseline (0 min); #P < 0.05 compared with HFD baseline (0 min). n = 4–6 each.
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of AdipoR1, AdipoR2 and APPL1 were not altered by HFD
feeding in either skeletal muscle or aorta (Fig. 5). The
insulin-stimulated Akt phosphorylation was not affected
by HFD in muscle (Fig. 6), but the insulin-stimulated Akt
and eNOS phosphorylation was blunted in aorta (Fig. 7) in
HFD animals. gAd alone did not alter the phosphorylation
of Akt, ERK1/2 or AMPK in either muscle or aorta from
HFD rats. However, administration of a single dose of
gAd before the insulin clamp markedly enhanced Akt and
eNOS phosphorylation in aorta which is totally blocked by
Compound C pretreatment. The insulin-stimulated ERK
pathway was intact in both muscle and aorta tissue in HFD
fed rats. Realizing that NO signalling may differ in small vs.
large arteries, we also measured plasma NO concentrations
in our in vivo studies. Insulin increased plasma NO
concentrations in LFD rats by 33% (30.9 ± 2.4 μM
vs.40.4 ± 2.0 μM, baseline vs. 120 min, P < 0.05). While
insulin failed to increase plasma NO concentrations in
HFD rats (28.6 ± 2.5 μM vs. 29.9 ± 3.2 μM, baseline
vs. 120 min, P = 0.72), administration of gAd restored
insulin-stimulated NO production to the levels seen in
LFD rats (27.5 ± 1.1 μM vs. 43.9 ± 5.1 μM, baseline vs.
120 min, P < 0.05).
Discussion
In the current study, we aimed to examine the
relationship between vascular function and metabolic
insulin responses and how adiponectin’s vascular actions
would affect insulin’s metabolic actions in muscle in the
insulin resistant state. We used muscle to assess insulin’s
metabolic action, muscle microvasculature to examine
insulin’s microvascular action which actively regulates
insulin’s metabolic action in muscle, and the distal
saphenous artery, which feeds to the microvasculature, to
examine vascular reactivity. We demonstrated that HFD
feeding engenders both adiponectin and insulin resistance
in the resistance arterioles and microvasculature while
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Figure 4. Administration of gAd ameliorates HFD-induced metabolic insulin resistance
Each rat was fed a HFD for 4 weeks and then received an I.P. injection of either gAd (0.4 µg (g body wt)−1) or
saline followed by a 2 h insulin clamp (3 mU kg−1 min−1) in the absence or presence of compound C or L-NAME.
LFD fed rats were used as control. A, time course of glucose infusion rate. B, steady state glucose infusion rate (C:
Compound C; L: L-NAME). ∗P < 0.05 compared with control; #P < 0.05 compared with HFD; @P < 0.05 compared
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Figure 5. HFD has no effect on Adipo R1/2 and APPL1 protein expression in either muscle (A) or aorta
(B)
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acute administration of gAd improves metabolic insulin
sensitivity by improving AMPK-mediated restoration
of microvascular insulin responses in HFD rats. These
findings extend our previous report that gAd enhances
insulin’s metabolic action in the insulin sensitive state via
muscle microvascular recruitment and increased muscle
delivery and action of insulin (Zhao et al. 2013), and
provide a logical explanation to adiponectin’s insulin
sensitization action in the insulin resistant state. It is
important to note that variations according to sex exist in
vascular function (Sader & Celermajer, 2002) and whether
our findings obtained in male rats can be extrapolated to
females warrants further investigation.
Adiponectin resistance is well recognized in liver,
adipose tissue and muscle, and is closely associated
with insulin resistance. Indeed, gAd responsiveness is
significantly reduced in skeletal muscle from obese/
diabetic patients (Bruce et al. 2005; Chen et al. 2005)
and animals fed a HFD (Mullen et al. 2007, 2009),
as well as in liver tissue from insulin receptor trans-
genic/knockout mice (Lin et al. 2007) or heart tissue from
HFD-induced diabetic mice (Yi et al. 2011). Reduced
vascular responsiveness to adiponectin has also been
reported in the aorta from hyperlipidaemic rats (Li et al.
2007) and resistance arteries of Zucker diabetic fatty rats
(Schmid et al. 2011). The significantly reduced vaso-
dilatation in isolated saphenous artery and the lack of
microvascular recruitment in vivo in HFD fed rats in
response to gAd administration in the current study
confirm the presence of adiponectin resistance in small
resistance artery as well as the microvascular bed. The
lack of gAd-induced AMPK phosphorylation in HFD
animals in our study lends further evidence of adiponectin
resistance in the insulin resistant state. Indeed, Mullen et al.
found that HFD feeding could totally abolish the acute
effect of gAd on AMPK phosphorylation in rat skeletal
muscle in as early as 3 days (Mullen et al. 2009). It is
very likely that in addition to hypoadiponectinaemia this
adiponectin resistance in the microvasculature contributes
to endothelial dysfunction and insulin resistance in
diabetic humans and animals. Inasmuch as adiponectin
activates AMPK, and we have in the current study shown
that Compound C totally blocked adiponectin’s effects
both ex vivo and in vivo (Figs 1 and 3) without affecting
microvascular parameters or blood pressure, we cannot
entirely rule out the involvement of other kinase pathways
in the gAd and HFD interaction due to the non-specific
effect of Compound C on other kinases.
The mechanisms underlying vascular adiponectin
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Figure 6. Protein phosphorylation in muscle of high-fat fed rats
A, Akt. B, AMPK. C, ERK1/2. ∗P < 0.05 compared with control; #P < 0.05 compared with HFD. n = 3–4. (ANOVA.)
P = Phosphorylated; T = Total.
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
J Physiol 593.17 Adiponectin improves microvascular insulin resistance 4075
vasodilatory action via AdipoR1 and AdipoR2-mediated
NO production through the AMPK–eNOS pathway
(Kadowaki & Yamauchi, 2005; Nedvı́dková et al. 2005). It
does not appear that HFD-induced vascular adiponectin
resistance is due to altered AdipoR1 or AdipoR2 expression
as these were unchanged in either muscle or aorta in
our study. Others have also noted that muscle AdipoR1
expression did not change after 4 weeks of a HFD (Mullen
et al. 2009) and that aortic AdipoR1/R2 expression did
not change until 16 weeks of HFD feeding (Li et al.
2010). A previous study showed that HFD-treated mice
had similar plasma adiponectin levels to those of control
mice and AdipoR2 expression was lower in aorta of db/db
mice compared with db/m+ mice (Wong et al. 2011).
This discrepancy probably resulted from differences in
species (rats vs. mouse) and disease models (diet model
vs. genetic diabetic model). In addition, the expression of
APPL1, an adaptor protein that is critical in the crosstalk
between the adiponectin and insulin signalling pathways
(Mao et al. 2006), was also not affected. This, coupled with
the failure to increase AMPK and eNOS phosphorylation
in aorta after gAd administration, strongly suggests
that vascular adiponectin resistance occurs downstream
of APPL1 and warrants further investigation. Caution
should be exercised when extrapolating aortic protein
expression data to small resistance arteries due to vascular
heterogeneity in protein expression.
Despite the fact that the HFD induced resistance to
the direct vasodilatory action of gAd in isolated distal
saphenous artery, administration of gAd was able to restore
the vasodilatory response to insulin. This is consistent
with many previous reports demonstrating that hypo-
adiponectinaemia is closely associated with endothelial
dysfunction, and adiponectin supplementation improves
endothelial function in the insulin resistant states (Ohashi
et al. 2006; Li et al. 2007; Lee et al. 2012). This ex vivo
study also helps explain our in vivo findings that acute
administration of gAd in HFD rats did not recruit muscle
microvasculature but completely restored muscle micro-
vascular insulin sensitivity, as insulin exerts its micro-
vascular actions via an endothelium dependent pathway
(Vincent et al. 2003). A recent study has also shown that
addition of gAd significantly attenuates impaired peri-
vascular adipose tissue control of insulin-induced vaso-
reactivity in muscle in db/db mice (Meijer et al. 2013).
Our findings that 4 weeks of HFD feeding significantly
raised plasma insulin concentrations and decreased
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Figure 7. Protein phosphorylation in aorta of HFD fed rats
A, Akt. B, AMPK. C, eNOS. D, ERK1/2. ∗P < 0.05 compared with control; #P < 0.05, compared with HFD. n = 3–4.
(ANOVA.)
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reverse association of insulin sensitivity and hypo-
adiponectinaemia. It has also been reported by Mullen
et al. that plasma adiponectin concentration is decreased
after 3 days of HFD feeding in rats (Mullen et al. 2009).
The finding that giving gAd prior to insulin infusion
significantly increased insulin-mediated glucose disposal
is certainly consistent with the literature suggesting that
adiponectin is an insulin sensitizer. Indeed, replenishment
of adiponectin via either injection or adenovirus-mediated
overexpression improves insulin sensitivity in rats (Fruebis
et al. 2001; Yamauchi et al. 2001, 2002, 2003; Satoh et al.
2005; Palanivel et al. 2007). Together with the observations
that gAd administration restores insulin’s muscle micro-
vascular responses and that inhibition of NO production
abolishes insulin-mediated increase in whole body glucose
disposal in HFD animals, our data strongly support our
previous conclusion that gAd enhances insulin action in
muscle via enhanced microvascular recruitment.
Though gAd administration completely restored
insulin-mediated microvascular recruitment, insulin-
stimulated whole body glucose disposal increased by only
30% and remained significantly lower than that in the
LFD fed rats. This is certainly consistent with a pre-
vious report demonstrating that insulin’s microvascular
action could contribute up to 40% of insulin-mediated
glucose disposal during insulin clamp (Vincent et al.
2003). Indeed, insulin-mediated Akt phosphorylation did
not change in muscle but significantly increased in aorta
in HFD fed rats received gAd. This may reflect muscle
adiponectin resistance as ample data have confirmed a
direct action of gAd on muscle cells to increase GLUT4
translocation and glucose uptake and improve insulin
actions in cultured muscle cells (Ceddia et al. 2005;
Wang et al. 2007). Whether chronic administration of
gAd directly improves the metabolic insulin sensitivity of
muscle remains to be clarified.
Our observations that 4 weeks of HFD abolished
insulin-mediated microvascular recruitment and decre-
ased insulin-stimulated glucose disposal by60% confirm
the presence of both microvascular and metabolic insulin
resistance in those animals. The close association of the
microvascular and metabolic insulin resistance during
HFD feeding once again demonstrates an important role of
muscle microvasculature in mediating insulin’s metabolic
action. We and others have confirmed that muscle micro-
vasculature actively regulates insulin delivery and action by
providing an endothelial exchange surface area (Vincent
et al. 2003, 2004; Chai et al. 2011, 2012; Fu et al. 2013;
Zhao et al. 2013). In addition, insulin stimulates its own

































































Figure 8. Schematic diagram showing the improvement of insulin sensitivity by gAd replenishment via
AMPK-mediated restoration of microvascular insulin response
Ad, adiponectin; AdipoR1/R2, adiponectin receptor 1/2; IR, insulin receptor. In the insulin sensitive
state, adiponectin and insulin are able to stimulate endothelial NO production through the
AdipoR1/2–APPL1–AMPK–eNOS and IR–Akt–eNOS pathways, respectively, leading to capillary recruitment and
increased insulin delivery to muscle and thus increased muscle glucose uptake. In the insulin-resistant state, both
adiponectin and insulin actions on endothelial cells are impaired, which results in reduced capillary response and
decreased muscle insulin delivery and action (muscle glucose uptake). Replenishment of adiponectin could restore
endothelial response to insulin.
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in the endothelial cells (Wang et al. 2008). In the presence
of insulin resistance, as seen in obesity or during systemic
lipid or tumour necrosis factor α infusion, microvascular
insulin responses are blunted (Clerk et al. 2006; Wang
et al. 2011, 2013). This could significantly decrease insulin
delivery to, and thus action in, muscle. Our findings that
gAd improves endothelial function and restores insulin’s
microvascular action are potentially clinically significant
and provide a logical explanation to the insulin-sensitizing
action of gAd in the insulin-resistant states.
In conclusion, HFD induces resistance to the vaso-
dilatory actions of both gAd and insulin but admin-
istration of gAd restores endothelial function and
improves metabolic insulin sensitivity in HFD animals
via an AMPK-mediated restoration of microvascular
insulin responses (Fig. 8). Though acute adiponectin
effects may bear no relation to chronic outcomes, and
it is impractical to use adiponectin administration as a
therapeutic modality, our results suggest that increasing
endogenous adiponectin levels and/or enhancing the
crosstalk between the adiponectin and insulin signalling
pathways might have a therapeutic potential for improving
metabolic insulin resistance and preventing cardiovascular
complications associated with diabetes via modulating
endothelial function and microvascular insulin sensitivity.
References
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa
J, Hotta K, Shimomura I, Nakamura T, Miyaoka K,
Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara
K, Muraguchi M, Ohmoto Y, Funahashi T & Matsuzawa Y
(1999). Paradoxical decrease of an adipose-specific protein,
adiponectin, in obesity. Biochem Biophys Res Commun 257,
79–83.
Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W &
Liu Z (2009). The vascular actions of insulin control its
delivery to muscle and regulate the rate-limiting step in
skeletal muscle insulin action. Diabetologia 52, 752–764.
Berg AH, Combs TP, Du X, Brownlee M & Scherer PE (2001).
The adipocyte-secreted protein Acrp30 enhances hepatic
insulin action. Nat Med 7, 947–953.
Bruce CR, Mertz VA, Heigenhauser GJ & Dyck DJ (2005). The
stimulatory effect of globular adiponectin on
insulin-stimulated glucose uptake and fatty acid oxidation is
impaired in skeletal muscle from obese subjects. Diabetes 54,
3154–3160.
Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G &
Sweeney G (2005). Globular adiponectin increases GLUT4
translocation and glucose uptake but reduces glycogen
synthesis in rat skeletal muscle cells. Diabetologia 48,
132–139.
Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W & Liu Z
(2012). Glucagon-like peptide 1 recruits microvasculature
and increases glucose use in muscle via a nitric
oxide-dependent mechanism. Diabetes 61, 888–896.
Chai W, Wang W, Dong Z, Cao W & Liu Z (2011).
Angiotensin II receptors modulate muscle microvascular
and metabolic responses to insulin in vivo. Diabetes 60,
2939–2946.
Chai W, Wu Y, Li G, Cao W, Yang Z & Liu Z (2008). Activation
of p38 mitogen-activated protein kinase abolishes
insulin-mediated myocardial protection against
ischemia-reperfusion injury. Am J Physiol Endocrinol Metab
294, E183–E189.
Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O’Brien PE,
Dixon JB, Cameron-Smith D, Kemp BE & Steinberg GR
(2005). Impaired activation of AMP-kinase and fatty acid
oxidation by globular adiponectin in cultured human
skeletal muscle of obese type 2 diabetics. J Clin Endocrinol
Metab 90, 3665–3672.
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR & Barrett EJ
(2006). Obesity blunts insulin-mediated microvascular
recruitment in human forearm muscle. Diabetes 55,
1436–1442.
Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S &
Barrett EJ (2004). The vasodilatory actions of insulin on
resistance and terminal arterioles and their impact on
muscle glucose uptake. Diabetes Metab Res Rev 20,
3–12.
Combs TP, Berg AH, Obici S, Scherer PE & RossettiL (2001).
Endogenous glucose production is inhibited by the
adipose-derived protein Acrp30. J Clin Invest 108,
1875–1881.
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Translational perspective
Adiponectin is a well-known insulin sensitizer. Hypoadiponectinaemia is closely associated with endothelial
dysfunction and insulin resistance in patients with, or animal models of, obesity and diabetes. Recent evidence
suggests that microvascular dysfunction contributes significantly to the development of metabolic insulin
resistance. Whether adiponectin ameliorates metabolic insulin resistance by affecting muscle microvascular
recruitment remains unknown. In the present study, we found that high-fat diet feeding causes microvascular
resistance to both globular adiponectin and insulin but replenishment of adiponectin improves endothelial
function and ameliorates metabolic insulin resistance by restoring AMPK-mediated microvascular insulin
responses. This suggests that globular adiponectin might have a therapeutic potential for improving insulin
resistance and preventing cardiovascular complications in patients with diabetes via modulation of micro-
vascular endothelial function and insulin sensitivity.
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